News - Global, Oncology


Current filters:


Popular Filters

1 to 25 of 36 results

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201


Finland-based drugmaker Orion Corp has entered into a global partnership with German pharma major Bayer…

BayerGlobalLicensingODM-201OncologyOrion CorpPharmaceuticalResearch

Oncology market growth slowing due to fewer breakthroughs and biosimilars, say IMS


The global oncology drug market reached a value of $91 billion in 2013 but growth in the area is slowing,…

Alternative medicineCancer CareGlobalHealth Medical PharmaIMS HealthOncologyOncologyPharmaceuticalResearch

Clinigen gains rights to SpePharm’s Savene

Clinigen gains rights to SpePharm’s Savene


The UK’s specialty pharma firm Clinigen Group says it has acquired rights to Savene (dexrazoxane) from…

Clinigen GroupGlobalLicensingNorgineOncologyPharmaceuticalSaveneSpePharma

Nanomedicines market to reach $177.6 billion globally in 2019


The global market for nanomedicine was valued at $78.54 billion in 2012 and is expected to reach a value…

BiotechnologyCardio-vascularGlobalMarkets & MarketingOncology

Baxter buys exclusive rights to CTI’s cancer drug pacritinib


USA-based companies Baxter International and Cell Therapeutics have entered into an exclusive worldwide…

Baxter InternationalCell TherapeuticsFinancialGlobalLicensingOncologypacritinibPharmaceutical

Uterine cancer treatments market in need of drugs with high efficacy and safety profiles


The uterine cancer treatments market has been forecast to increase at a compound annual growth rate (CAGR)…

GlobalMarkets & MarketingOncologyPharmaceutical

Radiopharmaceuticals market to hit a value of $7.9 billion by 2018


The radiopharmaceuticals market has been forecast to exceed a value of $7.9 billion by 2018, driven by…

Cardio-vascularGlobalMarkets & MarketingNeurologicalOncologyPharmaceutical

B-MS' nivolumab to lead NSCLC market with sales of $1.75 billion by 2022, says GlobalData


US pharma major Bristol-Myers Squibb's (NYSE: BMY) nivolumab will overtake proven blockbuster competitors…

Bristol-Myers SquibbGlobalMarkets & MarketingnivolumabOncologyPharmaceutical

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData


The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Clinigen acquires oncology support therapy Cardioxane from Novartis


UK-based Clinigen Group (LSE: CLIN) says it has acquired (AIM: CLIN) the oncology support therapy Cardioxane…

CardioxaneClinigen GroupGlobalMergers & AcquisitionsNovartisOncologyPharmaceutical

BRIC countries' breast cancer market to see 8% annual growth to 2017


The market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow…

GlaxoSmithKlineGlobalHerceptinMarkets & MarketingOncologyPharmaceuticalRocheTykerb

Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain


The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in…

BiotechnologyGleevecGlivecGlobalMarkets & MarketingNovartisOncologyPharmaceutical

New drug options for advanced prostate cancer


Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Sales of cancer pain therapies set to grow to $5.2 billion in the G7 by 2021


Sales of cancer pain therapies will increase to $5.2 billion in 2021 in leading seven markets (the USA,…

AmgenBiotechnologyDaiichi SankyodenosumabGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRanmarkXgeva

NSCLC market will Increase to over $6 billion in 2021, fueled largely by the entry of seven new agents


The entry of seven new agents into the non-small cell lung cancer (NSCLC) drug market - and in particular…

GlobalMarkets & MarketingOncologyPharmaceuticalResearch

Zeltia's Yondelis approved for sale in 10 new countries


Pharma Mar, a subsidiary of Spain's Grupo Zeltia (ZEL: MC), says it has been advised by its licensee…

GlobalJanssenJohnson & JohnsonOncologyPharmaceuticalPharmaMarRegulationYondelisZeltia

Prognosis for renal cell carcinoma market development


Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug…

Bristol-Myers SquibbGlaxoSmithKlineGlobalMarkets & MarketingnivolumabOncologyPfizerPharmaceuticalSutentVotrient

Prostate cancer drug market will more than double to $9.1 billion in 2021


The prostate cancer drug market will more than double, increasing from $4.1 billion in 2011 to $9.1 billion…

Astellas PharmaGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalXtandiZytiga

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021


Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021


While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Multiple myeloma drug market forecast to reach $7.2 billion in 2021


The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

1 to 25 of 36 results

Back to top